STONY BROOK, N.Y., Sept. 10, 2021 (SEND2PRESS NEWSWIRE) — iCell Gene Therapeutics, a clinical stage biopharmaceutical company focused on immunotherapies for hematologic malignancies, solid tumors, organ rejections and autoimmune disorders, today announced the publication of their clinical study utilizing cCAR T-cell immunotherapy to successfully treat a patient with lupus.
Archive | Drugs and Pharmaceuticals
Press Release: Kalyagen Announces Release of Free eBook on How to Optimize Health Using Stem Cells
By Send2Press Newswire on July 14, 2021 in AUSTIN, Texas, Books and Publishing, Business, Drugs and Pharmaceuticals, Press Releases
AUSTIN, Texas, July 14, 2021 (SEND2PRESS NEWSWIRE) — Kalyagen® has announced the release and availability of a free eBook, “The Stemregen Effect – Tapping into the Power of Your Own Stem Cells,” which provides an overview of how stem cells are the body’s repair system and how STEMREGEN®, a natural stem cell enhancer, has been […]
Press Release: Live-Online C. diff. Symposium developed to support and guide patients, families, and caregivers through a C. difficile illness
By Send2Press Newswire on June 29, 2021 in Business, Drugs and Pharmaceuticals, NonProfit and Charities, Press Releases, TAMPA, Fla.
TAMPA, Fla., June 29, 2021 (SEND2PRESS NEWSWIRE) — The C Diff Foundation will host a free, live-online, and interactive symposium on Friday, July 16, 2021 from 1 to 3 p.m. EDT. Sponsored by Seres Therapeutics, the event is designed for patients who are being treated for a C. diff. infection (CDI) in addition to those […]
Press Release: Pure MHC, LLC Announces Launch of its Peptide HLA Immunotherapy Data Resource following Collaboration with LifeNet Health
By Send2Press Newswire on March 16, 2021 in AUSTIN, Texas, Biotechnology, Business, Drugs and Pharmaceuticals, Press Releases, Product Launches
AUSTIN, Texas, March 16, 2021 (SEND2PRESS NEWSWIRE) — Pure MHC, LLC, a target discovery and development company, today announced the launch of its Peptide HLA Immunotherapy Data Resource (“PHIDR”), built through its collaboration with a trusted provider of transplant solutions and a leader in regenerative medicine, LifeNet Health.
Press Release: Pure Transplant Solutions Announces Collaboration with the University of Alabama at Birmingham to Develop Memory B Cell-Directed Diagnostics for HLA-Sensitized Patients
By Send2Press Newswire on March 11, 2021 in Alliances and Partnerships, Biotechnology, BIRMINGHAM, Ala., Business, Drugs and Pharmaceuticals, Press Releases, Surgery and Neurotechnology
AUSTIN, Texas and BIRMINGHAM, Ala., March 11, 2021 (SEND2PRESS NEWSWIRE) — Pure Transplant Solutions, LLC (PTS), a collaboration driven biotechnology company focused on the development of human leukocyte antigen (HLA)-based diagnostics and therapeutics within the field of transplantation, is proud to announce that it has entered into a collaboration agreement with The University of Alabama […]
Press Release: Zeteo Biomedical Receives US Patent for Innovative Sublingual Delivery Device for Vaccines and Pharmaceuticals
By Send2Press Newswire on March 10, 2021 in AUSTIN, Texas, Business, Drugs and Pharmaceuticals, Patent and Trademark, Press Releases
AUSTIN, Texas, March 10, 2021 (SEND2PRESS NEWSWIRE) — Zeteo Biomedical, a privately held, biomedical device company, announced today it has been awarded a United States Patent for its “Oral Delivery Device and Methods” (US Patent 10238577). This latest patent expands the capabilities of Zeteo’s ZEO Delivery Platform to systemically deliver drugs or biologics, into the […]
Press Release: Caisson Biotech, LLC and Heparinex, LLC Announce Positive Examination Report of European Patent and the Discovery of a New Class of Sugar Polymers
By Send2Press Newswire on February 23, 2021 in AUSTIN, Texas, Biotechnology, Business, Drugs and Pharmaceuticals, Patent and Trademark, Press Releases
AUSTIN, Texas and OKLAHOMA CITY, Okla., Feb. 23, 2021 (SEND2PRESS NEWSWIRE) — Caisson Biotech and parent company Heparinex are pleased to announce that they have received a positive examination report from the European Patent Office for a patent covering the chemoenzymatic production of heparosan utilized in the HEPtune® drug delivery platform. Once certified, the new […]
Press Release: Rescindo Therapeutics’ RSC-57 Receives FDA Orphan Drug Designation and Rare Pediatric Disease Designation for Kabuki Syndrome
CARY, N.C., Feb. 12, 2021 (SEND2PRESS NEWSWIRE) — Rescindo Therapeutics Inc., a drug discovery company dedicated to the development of new treatments for rare genetic disorders, announced today that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation and Rare Pediatric Disease Designation for the Company’s lead drug RSC-57, for the treatment […]
Press Release: Kalyagen Announces Launch of ‘Stem the Tide of Time’ Campaign Featuring NBA Hall of Fame Finalist Marques Johnson
By Send2Press Newswire on February 8, 2021 in Advertising and Marketing, AUSTIN, Texas, Business, Drugs and Pharmaceuticals, Press Releases
AUSTIN, Texas, Feb. 8, 2021 (SEND2PRESS NEWSWIRE) — Kalyagen is pleased to announce the launch of its “Stem the Tide of Time” social media campaign featuring former UCLA Bruin and Milwaukee Buck All-Star Marques Johnson to promote STEMREGEN;, a natural stem cell enhancer documented to increase the number of circulating stem cells by stimulating Endogenous […]
Press Release: Kalyagen™ Announces Launch of Clinical Trial to Evaluate STEMREGEN® and Stem Cells for Advanced Heart Failure Patients
By Send2Press Newswire on February 5, 2021 in AUSTIN, Texas, Business, Drugs and Pharmaceuticals, Press Releases
AUSTIN, Texas, Feb. 5, 2021 (SEND2PRESS NEWSWIRE) — Kalyagen™, along with the Sociedad Espanola de Medicina Regenerativa y Terapia Celular (the “Spanish Society of Regenerative Medicine and Cell Therapy”), is pleased to announce the launch of a multicenter clinical trial, “The Effect of Stemregen and Adipose Stroma Vascular Fraction (SVF) Either Individually or in Combination […]